Tirzepatide 20mg Smartpen
Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist, Tirzepatide accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).
Mechanism of Action
- GLP-1: Suppresses appetite and increases feelings of fullness after eating.
- GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.
Benefits
- Average weight loss of 24.7% after 72 weeks
- Reduces appetite and cravings
- Enhances satiety and energy balance
- Supports fat oxidation and metabolism
- Improves insulin sensitivity and blood sugar control
An 80 IU smart pen is a reusable, dose-tracking injection device designed to deliver up to 80 international units (IU) of medication. It allows users to dial precise doses in small increments and features safeguards to help prevent dosing errors. Each Smart pen will come with a metal case with 4 x 31G 6mm insulin needles. Once finished you are able to purchase the refill cartridges upon request.
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use and must not be misused in any way that contravenes MHRA regulations or applicable laws.